{
  "trial_id": "NCT04749810",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "vaccinated against meningococcal infections were treated by Elizaria\u00ae",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The study is planned to include at least 50 patients receiving Elizaria\u00ae for the aHUS treatment.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The study will consist of a screening period of up to 4 weeks, including, if necessary, immunization with meningococcal vaccine, a treatment period of 52 weeks.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Medication will be prescribed in accordance with routine medical practice.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Accordingly to minimize the risks and subjectivity of assessments the methods adopted in the routine practice of treating patients with aHUS will be used.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Investigators enroll patients with aHUS diagnosis who have indications for pathogenetic therapy and who are receiving Elizaria\u00ae under the government program.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients will receive medication in accordance with the established requirements of national standards and protocols for the treatment of patients with aHUS.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "The registration of the amount of the drug used will be carried out on the basis of information in the Patient Diaries, as well as primary documentation.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Written informed consent to study participation.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Male and female patients aged 2 months and older with documented atypical hemolytic uremic syndrome (aHUS) diagnosis.",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Intolerance to eculizumab, or other components of the drug.",
      "label": "triggers",
      "evidence": "quote"
    }
  ],
  "notes": "The patient has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%. He was treated with plasma exchange and corticosteroids.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT04749810",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}